Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds physicians will prescribe Abbott Laboratories' Humira at the expense of Amgen/Wyeth's Enbrel, Genentech's Raptiva, methotrexate, and Centocor/Schering Plough's Remicade upon its expected approval for psoriasis in 2007. According to the new Treatment Algorithm Insight Series report entitled Treatment Algorithms for Psoriasis, physicians suggest that the main factors driving Humira's uptake are its efficacy in clinical trials and its side effect/safety profile.

The report also finds that physicians are optimistic about payors making biologics a more cost-effective option.

"Forty one percent of dermatologists and 43% of primary care physicians we surveyed believe that in the next two years biologics will be reimbursed at lower copays," said Madhuri Borde, analyst at Decision Resources. "Fifty percent of dermatologists and 36% of primary care physicians we surveyed think that they will be increasingly allowed to prescribe biologics without prior approval/authorization."

Biologics held the greatest share of patients in third-line therapy, in which they accounted for 41.6% of prescriptions. Enbrel was the leading biologic agent overall, capturing seven times the patient share of the remaining biologics as a second-line agent and more than four times the others as a third-line agent.

Treatment Algorithms for Psoriasis allows pharmaceutical organizations to quantify lines of therapy through primary research and patient-level data. Users can:

  * Understand current treatment patterns and anticipate future market     dynamics   * Drive product growth through accurate knowledge of a product's     positioning among the lines of therapy and why physicians use it at that     point   * Target specific competitors that are preceding or following a product     and benefit from actionable analysis of the path to treatment and     physicians' decision parameters   * Develop more sophisticated market-forecasting patient-flow models based     on the unique, accurate information regarding the percentage of patients     receiving a product at specific stages in the line of therapy    About Treatment Algorithm Insight Series 

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics® to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

For each disease examined, Decision Resources' Treatment Algorithms Insight Series provides:

  * Summary of U.S. medical practice based on interviews with leading     experts in the field   * Qualitative diagnosis/referral/treatment algorithm for the United States   * Drug usage by lines of therapy (1st, 2nd, 3rd line)   * Discussion of key freeform combinations by lines of therapy   * Product share (class and specific compound level) within each line of     therapy (1st, 2nd, 3rd line)   * Progression of therapy from key 1st line products   * Pathway to key therapies from previous therapies   * Qualitative analysis of 2-year forecast incorporating upcoming launches,     changes in reimbursement, etc.    About Decision Resources 

Decision Resources, Inc., ( is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Elizabeth Marshall   Decision Resources, Inc.   781-296-2563 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

Increased Use of Wyeth's Mylotarg and Launches of New Drugs Will More Than Double the Acute Myeloid Leukemia Market By 2015

View Now